Immunocore Holdings PLC
NASDAQ:IMCR
Immunocore Holdings PLC
NASDAQ:IMCR
Price:
60.23 USD
1.29%
Market Closed
Updated:
May 5, 2024
Immunocore Holdings PLC
Operating Income
|
Immunocore Holdings PLC
Operating Income Peer Comparison
Comparables:
CNTA
EXAI
AUTL
BCYC
GNS
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Operating Income
-£59.6m
|
CAGR 3-Years
13%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Operating Income
-$171.3m
|
CAGR 3-Years
-154%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Exscientia PLC
NASDAQ:EXAI
|
Operating Income
-£174.5m
|
CAGR 3-Years
-80%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Operating Income
-$175.5m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Operating Income
-$179.9m
|
CAGR 3-Years
-47%
|
CAGR 5-Years
-52%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Operating Income
£53m
|
CAGR 3-Years
8%
|
CAGR 5-Years
4%
|
CAGR 10-Years
4%
|
See Also
What is Immunocore Holdings PLC's Operating Income?
Operating Income
-59.6m
GBP
-59.6m
GBP
Based on the financial report for Dec 31, 2023, Immunocore Holdings PLC's Operating Income amounts to -59.6m GBP.
What is Immunocore Holdings PLC's Operating Income growth rate?
Operating Income CAGR 5Y
9%
9%
Over the last year, the Operating Income growth was -45%. The average annual Operating Income growth rates for Immunocore Holdings PLC have been 13% over the past three years , 9% over the past five years .
You don't have any saved screeners yet
